Free Submission Public Relations & NewsPR-inside.com
 
DeutschEnglish

Get the latest news
with our RSS feed
rss feed
Add to My Yahoo!
More information
Business

OSI Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference on Tuesday, November 3, 2009


Print article Print article
Refer this article Refer to a friend
© Business Wire 2009
2009-10-27 16:10:04 -

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that OSI Management will present at the Oppenheimer Healthcare Conference in New York, NY on Tuesday, November 3, 2009 at 3:20pm (Eastern Time) and will provide an overview on the Company’s product portfolio and business developments.

The presentation will be webcast live and may be accessed by visiting OSI’s website at www.osip.com :

cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. .

A replay of the webcast will also be available on the Company’s website until November 17, 2009.

About OSI Pharmaceuticals


OSI Pharmaceuticals is committed to "shaping medicine and changing lives" by discovering, developing and commercializing high-quality, novel and differentiated targeted medicines designed to extend life and improve the quality of life for patients with cancer and diabetes/obesity. For additional information about OSI, please visit www.osip.com : .

This news release contains forward-looking statements. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others, OSI's and its collaborators' abilities to effectively market and sell Tarceva and to expand the approved indications for Tarceva, OSI’s ability to protect its intellectual property rights, safety concerns regarding Tarceva, competition to Tarceva and OSI’s drug candidates from other biotechnology and pharmaceutical companies, the completion of clinical trials, the effects of FDA and other governmental regulation, including pricing controls, OSI's ability to successfully develop and commercialize drug candidates, and other factors described in OSI Pharmaceuticals' filings with the Securities and Exchange Commission.

OSI Pharmaceuticals, Inc.Kathy Galante (investors/media)631-962-2000Senior
DirectorKim Wittig (media)631-962-2000DirectororBurns
McClellan, Inc. (representing OSI)Justin Jackson/Kathy Nugent

(media)212-213-0006


Disclaimer: (c) 2009 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Terms & Conditions | Privacy | About us | Contact PR-inside.com